

Carmine Zoccali

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1843647/publications.pdf>

Version: 2024-02-01

376
papers

24,430
citations

8181

76
h-index

9589

142
g-index

385
all docs

385
docs citations

385
times ranked

23949
citing authors

#	ARTICLE	IF	CITATIONS
1	Is the KDIGO Systolic Blood Pressure Target $\leq 120\text{ mmHg}$ for Chronic Kidney Disease Appropriate in Routine Clinical Practice?. <i>Hypertension</i> , 2022, 79, 4-11.	2.7	24
2	Extrapolated normative GFR data for living kidney donation. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 301-304.	2.3	0
3	Detecting and Treating Lung Congestion with Kidney Failure. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 757-765.	4.5	5
4	Early morning hemodynamic changes and left ventricular hypertrophy and mortality in hemodialysis patients. <i>Journal of Nephrology</i> , 2022, , .	2.0	1
5	Dystrophic Muscle Affects Motoneuron Axon Outgrowth and NMJ Assembly. <i>Advanced Materials Technologies</i> , 2022, 7, .	5.8	6
6	Needleless Ablation of Osteoid Osteoma and Osteoblastoma: The Emergent Role of MRgFUS. <i>Journal of Clinical Medicine</i> , 2022, 11, 128.	2.4	8
7	Custom Massive Allograft in a Case of Pelvic Bone Tumour: Simulation of Processing with Computerised Numerical Control vs. Robotic Machining. <i>Journal of Clinical Medicine</i> , 2022, 11, 2781.	2.4	2
8	The chronology of the clinical cardiorenal links and health outcomes: problematic issues of the cardiorenal syndrome construct. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 2300-2302.	0.7	3
9	Interventional Radiology in the Management of Metastases and Bone Tumors. <i>Journal of Clinical Medicine</i> , 2022, 11, 3265.	2.4	15
10	Massive bone allograft engineered with autologous vessels: A new perspective for the future. <i>Hand Surgery and Rehabilitation</i> , 2022, , .	0.4	1
11	Undernutrition in childhood and adolescence and atherosclerosis in adult life. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 849-851.	2.6	0
12	The IlluminOss [®] photodynamic bone stabilization system for pathological osteolyses and fractures of the humerus: indications, advantages and limits in a series of 12 patients at 24 months of minimum follow-up. <i>BMC Musculoskeletal Disorders</i> , 2021, 22, 63.	1.9	7
13	Epidemiology of hyperkalemia in CKD patients under nephrological care: a longitudinal study. <i>Internal and Emergency Medicine</i> , 2021, 16, 1803-1811.	2.0	6
14	Antibacterial hydrogel coating in joint mega-prosthesis: results of a comparative series. <i>European Journal of Orthopaedic Surgery and Traumatology</i> , 2021, 31, 1647-1655.	1.4	12
15	Sleep Apnea as a Cardiorenal Risk Factor in CKD and Renal Transplant Patients. <i>Blood Purification</i> , 2021, 50, 642-648.	1.8	10
16	Novel Therapeutic Options for Cardiovascular Disease with CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 682-684.	4.5	0
17	A New Proximal Femur Reconstruction Technique after Bone Tumor Resection in a Very Small Patient: An Exemplificative Case. <i>Children</i> , 2021, 8, 442.	1.5	2
18	CT radiomics-based machine learning classification of atypical cartilaginous tumours and appendicular chondrosarcomas. <i>EBioMedicine</i> , 2021, 68, 103407.	6.1	35

#	ARTICLE	IF	CITATIONS
19	Wide Surgery in the Cervical Spine: Indications, Results, and Complications in a Series of 30 Patients Affected by Primary Bone Tumors. <i>World Neurosurgery</i> , 2021, 155, e240-e248.	1.3	1
20	3D-Printed Titanium Custom-Made Prostheses in Reconstruction after Pelvic Tumor Resection: Indications and Results in a Series of 14 Patients at 42 Months of Average Follow-Up. <i>Journal of Clinical Medicine</i> , 2021, 10, 3539.	2.4	13
21	Osteoblastoma: When the Treatment Is Not Minimally Invasive, an Overview. <i>Journal of Clinical Medicine</i> , 2021, 10, 4645.	2.4	3
22	Neuropeptide Y as a risk factor for cardiorenal disease and cognitive dysfunction in chronic kidney disease: translational opportunities and challenges. <i>Nephrology Dialysis Transplantation</i> , 2021, 37, ii14-ii23.	0.7	11
23	Management of Osteoblastoma and Giant Osteoid Osteoma with Percutaneous Thermoablation Techniques. <i>Journal of Clinical Medicine</i> , 2021, 10, 5717.	2.4	8
24	The giant aggressive chondroma: A rare entity, a difficult approach. <i>Journal of Orthopaedics</i> , 2020, 18, 181-184.	1.3	1
25	Lung ultrasound to detect and monitor pulmonary congestion in patients with acute kidney injury in nephrology wards: a pilot study. <i>Journal of Nephrology</i> , 2020, 33, 335-341.	2.0	7
26	FGF23 and the PTH response to paricalcitol in chronic kidney disease. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13196.	3.4	8
27	Endothelial Dysfunction in Chronic Kidney Disease, from Biology to Clinical Outcomes: A 2020 Update. <i>Journal of Clinical Medicine</i> , 2020, 9, 2359.	2.4	123
28	Long-Term Changes in Sleep Disordered Breathing in Renal Transplant Patients: Relevance of the BMI. <i>Journal of Clinical Medicine</i> , 2020, 9, 1739.	2.4	5
29	Sleep-Disordered Breathing and 24-Hour Ambulatory Blood Pressure Monitoring in Renal Transplant Patients: Longitudinal Study. <i>Journal of the American Heart Association</i> , 2020, 9, e016237.	3.7	8
30	Should We Continue Assessing Glomerular Filtration Rate with the Cockcroft-Gault Formula in NOAC-Treated Patients? The Magnitude of the Problem. <i>Journal of Clinical Medicine</i> , 2020, 9, 1893.	2.4	8
31	Evolution of the imaging features of osteoid osteoma treated with RFA or MRgFUS during a long-term follow-up: a pictorial review with clinical correlations. <i>Radiologia Medica</i> , 2020, 125, 578-584.	7.7	34
32	En bloc resection in patients younger than 16 years affected by primary spine tumors: indications, results and complications in a series of 22 patients. <i>European Spine Journal</i> , 2020, 29, 3135-3147.	2.2	8
33	The advantages of carbon fiber based orthopedic devices in patients who have to undergo radiotherapy. <i>Acta Biomedica</i> , 2020, 91, e2020057.	0.3	5
34	18F-FDG PET/CT in the evaluation of cartilaginous bone neoplasms: the added value of tumor grading. <i>Annals of Nuclear Medicine</i> , 2019, 33, 813-821.	2.2	23
35	A single number for advocacy and communication worldwide more than 850 million individuals have kidney diseases. <i>Kidney International</i> , 2019, 96, 1048-1050.	5.2	283
36	Magnetic resonance-guided focused ultrasound surgery treatment of non-spinal intra-articular osteoblastoma: feasibility, safety, and outcomes in a single-center retrospective analysis. <i>International Journal of Hyperthermia</i> , 2019, 36, 767-774.	2.5	15

#	ARTICLE	IF	CITATIONS
37	Magnetic-resonance-guided focused ultrasound treatment of non-spinal osteoid osteoma in children: multicentre experience. <i>Pediatric Radiology</i> , 2019, 49, 1209-1216.	2.0	49
38	En bloc spondylectomy in patients older than 60 years: indications, results and complications in a series of 37 patients. <i>European Spine Journal</i> , 2019, 28, 1512-1519.	2.2	10
39	Percutaneous management of bone metastases: state of the art, interventional strategies and joint position statement of the Italian College of MSK Radiology (ICoMSKR) and the Italian College of Interventional Radiology (ICIR). <i>Radiologia Medica</i> , 2019, 124, 34-49.	7.7	67
40	Is the Posterior-Only Approach Sufficient for Treating Cervical Spine Metastases? The Evidence from a Case Series. <i>World Neurosurgery</i> , 2019, 122, e783-e789.	1.3	8
41	Anterior robotic approach in en-bloc sacrectomy: a preliminary experience. <i>Journal of Robotic Surgery</i> , 2019, 13, 53-59.	1.8	5
42	Intralesional vs. extralesional procedures for low-grade central chondrosarcoma: a systematic review of the literature. <i>Archives of Orthopaedic and Trauma Surgery</i> , 2018, 138, 929-937.	2.4	23
43	Obestatin, a Ghrelin-Cognate Protein, and Clinical Outcomes in Hemodialysis Patients. <i>American Journal of Nephrology</i> , 2018, 47, 251-253.	3.1	1
44	The Ebb and Flow of Echocardiographic Cardiac Function Parameters in Relationship to Hemodialysis Treatment in Patients with ESRD. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 1372-1381.	6.1	29
45	Mutations in the GLA Gene and LysoGb3: Is It Really Anderson-Fabry Disease?. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3726.	4.1	63
46	A New Treatment for Calciphylaxis in Hemodialysis Patients?. <i>American Journal of Nephrology</i> , 2018, 48, 165-167.	3.1	0
47	Fibrous dysplasia: an unusual case of a very aggressive form with costo-vertebral joint destruction and invasion of the contralateral D7 vertebral body. <i>Skeletal Radiology</i> , 2018, 47, 1571-1576.	2.0	1
48	Mapping Progress in Reducing Cardiovascular Risk with Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1432-1434.	4.5	17
49	The dual mobility cup in muscular skeletal oncology: rationale and indications. <i>International Orthopaedics</i> , 2017, 41, 447-453.	1.9	13
50	Obesity and Kidney Disease: Hidden Consequences of the Epidemic. <i>Blood Purification</i> , 2017, 43, 346-354.	1.8	12
51	Obesity and Kidney Disease: Hidden Consequences of the Epidemic. <i>Nephron</i> , 2017, 135, 243-251.	1.8	10
52	Salvage Revision Surgery After Inappropriate Approach for Primary Spine Tumors: Long Term Follow-Up in 56 Cases. <i>World Neurosurgery</i> , 2017, 98, 329-333.	1.3	17
53	Moderator's view: Predictive models: a prelude to precision nephrology. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 756-758.	0.7	4
54	Obesity and Kidney Disease: Hidden Consequences of the Epidemic. <i>American Journal of Nephrology</i> , 2017, 45, 283-291.	3.1	1,557

#	ARTICLE	IF	CITATIONS
55	Long-Term Progression of Coronary Artery Calcification Is Independent of Classical Risk Factors, C-Reactive Protein, and Parathyroid Hormone in Renal Transplant Patients. <i>CardioRenal Medicine</i> , 2017, 7, 284-294.	1.9	9
56	An unusual localization of chondroblastoma: The triradiate cartilage; from a case report a reconstructive technique proposal with imaging evolution. <i>Journal of Clinical Orthopaedics and Trauma</i> , 2017, 8, S48-S52.	1.5	28
57	Obesity and Kidney Disease: Hidden Consequences of the Epidemic. <i>Kidney Diseases (Basel, Switzerland)</i> , 2017, 3, 33-41.	2.5	12
58	Effect of Vitamin D Receptor Activation on the AGE/RAGE System and Myeloperoxidase in Chronic Kidney Disease Patients. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-7.	4.0	7
59	Vitamin D and methylarginines in chronic kidney disease (CKD). <i>PLoS ONE</i> , 2017, 12, e0185449.	2.5	3
60	Arterial Stiffness as a Cardiovascular Risk Factor in Stage 5D Chronic Kidney Disease Patients: An Age Affair. <i>American Journal of Nephrology</i> , 2017, 45, 69-71.	3.1	2
61	Surgery: Treatment of Oligometastatic Disease. , 2017, , 147-161.		2
62	Reconstruction after musculoskeletal sarcomas: how to avoid a surgical trap. <i>Minerva Surgery</i> , 2017, 72, 108-120.	0.6	0
63	Oxidative Stress as Estimated by Gamma-Glutamyl Transferase Levels Amplifies the Alkaline Phosphatase-Dependent Risk for Mortality in ESKD Patients on Dialysis. <i>Oxidative Medicine and Cellular Longevity</i> , 2016, 2016, 1-7.	4.0	17
64	Bracing After Surgical Stabilization of Thoracolumbar Fractures: A Systematic Review of Evidence, Indications, and Practices. <i>World Neurosurgery</i> , 2016, 93, 221-228.	1.3	16
65	A computer-assisted navigation technique to perform bone tumor resection without dedicated software. <i>Computer Assisted Surgery</i> , 2016, 21, 166-171.	1.3	1
66	The Carbofixâ„¢ â€œPiccolo Proximal femur nailâ€: A new perspective for treating proximal femur lesion. A technique report. <i>Journal of Orthopaedics</i> , 2016, 13, 343-346.	1.3	15
67	The Tokuhashi score: effectiveness and pitfalls. <i>European Spine Journal</i> , 2016, 25, 673-678.	2.2	55
68	Residual neurological function after sacral root resection during en-bloc sacrectomy: a systematic review. <i>European Spine Journal</i> , 2016, 25, 3925-3931.	2.2	37
69	The Surgical Anatomy of the Lumbosacroiliac Triangle: A Cadaveric Study. <i>World Neurosurgery</i> , 2016, 88, 36-40.	1.3	10
70	Radiofrequency ablation versus magnetic resonance guided focused ultrasound surgery for minimally invasive treatment of osteoid osteoma: a propensity score matching study. <i>European Radiology</i> , 2016, 26, 2472-2481.	4.5	66
71	Arthroscopic patterns of the poster-medial aspect of the knee joint: classification of the gastrocnemiussemimembranosus gateway and its relationship with Baker's cyst. <i>Muscles, Ligaments and Tendons Journal</i> , 2016, 6, 492-498.	0.3	4
72	Surgical Site Infections in Treatment of Musculoskeletal Tumors: Experience from a Single Oncologic Orthopedic Institution. <i>Journal of Orthopedic Oncology</i> , 2016, 02, .	0.1	1

#	ARTICLE	IF	CITATIONS
73	The Role of Deconditioning in the End-Stage Renal Disease Myopathy: Physical Exercise Improves Altered Resting Muscle Oxygen Consumption. <i>American Journal of Nephrology</i> , 2015, 41, 329-336.	3.1	41
74	Epithelioid hemangioendothelioma of the spine: results at seven years of average follow-up in a series of 10 cases surgically treated and a review of literature. <i>European Spine Journal</i> , 2015, 24, 2156-2164.	2.2	18
75	Surgical anatomy of the minimally invasive lateral lumbar approach. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 456-459.	1.5	19
76	Seven essential tools of a cardiologist's survival kit. <i>International Journal of Cardiology</i> , 2015, 191, 87-89.	1.7	0
77	The surgical neurovascular anatomy relating to partial and complete sacral and sacroiliac resections: a cadaveric, anatomic study. <i>European Spine Journal</i> , 2015, 24, 1109-1113.	2.2	26
78	The surgical vascular anatomy of the minimally invasive lateral lumbar interbody approach: a cadaveric and radiographic analysis. <i>European Spine Journal</i> , 2015, 24, 906-911.	2.2	17
79	A paradigm for the evaluation and management of spinal coccidioidomycosis. , 2015, 6, 107.		15
80	Assessment of arterial stiffness for clinical and epidemiological studies: methodological considerations for validation and entry into the European Renal and Cardiovascular Medicine registry. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 232-239.	0.7	81
81	Association of a Polymorphism in a Gene Encoding a Urate Transporter with CKD Progression. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 1059-1065.	4.5	51
82	Phosphate levels in patients treated with low-flux haemodialysis, pre-dilution haemofiltration and haemodiafiltration: post hoc analysis of a multicentre, randomized and controlled trial. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1239-1246.	0.7	16
83	Giant cell tumor of bone in a patient with diagnosis of primary hyperparathyroidism: a challenge in differential diagnosis with brown tumor. <i>Skeletal Radiology</i> , 2014, 43, 693-697.	2.0	24
84	Vascular calcification in chronic kidney disease: are biomarkers useful for probing the pathobiology and the health risks of this process in the clinical scenario?. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1275-1284.	0.7	50
85	The role of minimally invasive lateral lumbar interbody fusion in sagittal balance correction and spinal deformity. <i>European Spine Journal</i> , 2014, 23, 699-704.	2.2	64
86	A multiplanar complex resection of a low-grade chondrosarcoma of the distal femur guided by K-wires previously inserted under CT-guide: a case report. <i>BMC Surgery</i> , 2014, 14, 52.	1.3	4
87	Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. <i>Lancet, The</i> , 2014, 383, 1831-1843.	13.7	341
88	Snoring Amplifies the Risk of Heart Failure and Mortality in Dialysis Patients. <i>American Journal of Nephrology</i> , 2014, 39, 536-542.	3.1	15
89	An unusual case of lumbar paravertebral myositis ossificans mimicking muscular skeletal tumor. <i>Musculoskeletal Surgery</i> , 2013, 97, 251-253.	1.5	4
90	Asymmetric dimethylarginine predicts survival in the elderly. <i>Age</i> , 2013, 35, 2465-2475.	3.0	31

#	ARTICLE	IF	CITATIONS
91	Albuminuria in the Normal Range. <i>Journal of the American College of Cardiology</i> , 2013, 61, 1634-1636.	2.8	1
92	Obesity and nephrology: results of a knowledge and practice pattern survey. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, iv99-iv104.	0.7	33
93	The quality of reporting in clinical research: the CONSORT and STROBE initiatives. <i>Aging Clinical and Experimental Research</i> , 2013, 25, 9-15.	2.9	31
94	Uric Acid, Hypertension, and Cardiovascular and Renal Complications. <i>Current Hypertension Reports</i> , 2013, 15, 531-537.	3.5	45
95	Pelvic sacral and hemi lumbar spine resection of low grade pelvic chondrosarcoma: A multistage procedure involving vascular bypass, spine fixation and vascular exclusion. <i>Orthopaedics and Traumatology: Surgery and Research</i> , 2013, 99, 875-879.	2.0	7
96	Joint effect of insulin signaling genes on cardiovascular events and on whole body and endothelial insulin resistance. <i>Atherosclerosis</i> , 2013, 226, 140-145.	0.8	23
97	A cyanoacrylate and silastic patch to reduce the risk of opening of the tumor: Technical note. <i>European Journal of Surgical Oncology</i> , 2013, 39, 44-45.	1.0	3
98	Pulmonary Hypertension in CKD. <i>American Journal of Kidney Diseases</i> , 2013, 61, 612-622.	1.9	119
99	Longitudinal Analysis of Vascular Function and Biomarkers of Metabolic Bone Disorders before and after Renal Transplantation. <i>American Journal of Nephrology</i> , 2013, 37, 126-134.	3.1	39
100	FGF23: A Mature Renal and Cardiovascular Risk Factor?. <i>Blood Purification</i> , 2013, 36, 52-57.	1.8	24
101	When do we need competing risks methods for survival analysis in nephrology?. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 2670-2677.	0.7	510
102	The use of echocardiography in observational clinical trials: the EURECA-m registry. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 19-23.	0.7	15
103	Multiple imputation: dealing with missing data. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 2415-2420.	0.7	99
104	Catheter-based renal denervation as a novel treatment for loin pain haematuria syndrome. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 2197-2199.	0.7	7
105	Longitudinal association of body mass index and waist circumference with left ventricular mass in hypertensive predialysis chronic kidney disease patients. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, iv136-iv145.	0.7	6
106	Resistin and all-cause and cardiovascular mortality: effect modification by adiponectin in end-stage kidney disease patients. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, iv181-iv187.	0.7	30
107	Phosphate attenuates the anti-proteinuric effect of very low-protein diet in CKD patients. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 632-640.	0.7	73
108	Spleen IL-10, a key player in obesity-driven renal risk. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 1061-1064.	0.7	9

#	ARTICLE	IF	CITATIONS
109	Effects of weight loss on renal function in obese CKD patients: a systematic review. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, iv82-iv98.	0.7	167
110	Use of phosphate-binding agents is associated with a lower risk of mortality. <i>Kidney International</i> , 2013, 84, 998-1008.	5.2	136
111	Lung congestion as a hidden threat in end-stage kidney disease: a call to action. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 2657-2660.	0.7	12
112	The new NDT series Ideas, Conjectures and Refutations (ICR): elegance in nephrology research. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 1384-1384.	0.7	0
113	Pulmonary Congestion Predicts Cardiac Events and Mortality in ESRD. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 639-646.	6.1	221
114	Obesity in CKD—What Should Nephrologists Know?. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 1727-1736.	6.1	174
115	Asymptomatic Pulmonary Congestion and Physical Functioning in Hemodialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1343-1348.	4.5	50
116	Influence of Body Mass Index on the Association of Weight Changes with Mortality in Hemodialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1725-1733.	4.5	49
117	Procalcitonin and the inflammatory response to salt in essential hypertension. <i>Journal of Hypertension</i> , 2013, 31, 1424-1430.	0.5	23
118	Age, stage and biomarkers for the definition of CKD: a construction in progress. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 1919-23.	2.3	0
119	A new technique to perform pelvic osteotomy using Gigli saw. <i>Journal of Surgical Oncology</i> , 2013, 108, 136-136.	1.7	2
120	Long-term visit-to-visit office blood pressure variability increases the risk of adverse cardiovascular outcomes in patients with chronic kidney disease. <i>Kidney International</i> , 2013, 84, 381-389.	5.2	65
121	Instrumental variable analysis. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 1694-1699.	0.7	22
122	Letter to the editor about the reviewer comment to our article entitled “Procalcitonin and the inflammatory response to salt in essential hypertension. <i>Journal of Hypertension</i> , 2013, 31, 1724.	0.5	0
123	Risk prediction models. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 1975-1980.	0.7	36
124	Homoarginine and Mortality in Pre-Dialysis Chronic Kidney Disease (CKD) Patients. <i>PLoS ONE</i> , 2013, 8, e72694.	2.5	35
125	Estimated Glomerular Filtration Rate, All-Cause Mortality and Cardiovascular Diseases Incidence in a Low Risk Population: The MATISS Study. <i>PLoS ONE</i> , 2013, 8, e78475.	2.5	38
126	The fat-mass and obesity-associated gene (FTO) predicts mortality in chronic kidney disease of various severity. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, iv58-iv62.	0.7	15

#	ARTICLE	IF	CITATIONS
127	Pulmonary Congestion and Physical Functioning in Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2012, 32, 531-536.	2.3	28
128	Predictors of haemoglobin levels and resistance to erythropoiesis-stimulating agents in patients treated with low-flux haemodialysis, haemofiltration and haemodiafiltration: results of a multicentre randomized and controlled trial. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 3594-3600.	0.7	39
129	Vitamin D Therapy and Cardiac Structure and Function in Patients With Chronic Kidney Disease. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 674.	7.4	495
130	Assessment of obesity in chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2012, 21, 641-646.	2.0	56
131	Thyroid Function and Clinical Outcomes in Kidney Failure. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 12-14.	4.5	22
132	Insulin resistance and left ventricular hypertrophy in end-stage renal disease: association between the ENPP1 gene and left ventricular concentric remodelling. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 661-666.	0.7	9
133	Tissue inhibitor of metalloproteinases (TIMP-1), genetic markers of insulin resistance and cardiomyopathy in patients with kidney failure. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 2440-2445.	0.7	3
134	The effect of increasing age on the prognosis of non-dialysis patients with chronic kidney disease receiving stable nephrology care. <i>Kidney International</i> , 2012, 82, 482-488.	5.2	75
135	eNOS and Caveolin-1 Gene Polymorphisms Interaction and Intima Media Thickness: A Proof of Concept Study in ESRD Patients. <i>American Journal of Hypertension</i> , 2012, 25, 103-108.	2.0	15
136	European guidelines on when to start dialysis: check the facts first before commenting. <i>Kidney International</i> , 2012, 81, 1149.	5.2	1
137	Chest ultrasound and hidden lung congestion in peritoneal dialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 3601-3605.	0.7	71
138	Hepatocyte Growth Factor and Cardiomyopathy in Dialysis Patients. <i>Hypertension</i> , 2012, 60, e24; author reply e25-6.	2.7	1
139	Report from the Editorial Offices. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 1-3.	0.7	1
140	The burden of physical inactivity in chronic kidney disease: is there an exit strategy?. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 2143-2145.	0.7	24
141	Pulmonary hypertension in dialysis patients: a prevalent, risky but still uncharacterized disorder. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 3674-3677.	0.7	7
142	Hypertension and cardiovascular risk in chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, iv1-iv1.	0.7	1
143	Chemotherapeutically Induced Cutaneous Tuberculosis after BCG Injection in a Patient with Pelvic Osteosarcoma. <i>Surgical Infections</i> , 2012, 13, 406-408.	1.4	3
144	Antidepressants for depression in stage 3-5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP)*. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 3736-3745.	0.7	124

#	ARTICLE	IF	CITATIONS
145	Pro-inflammatory cytokines and bone fractures in CKD patients. An exploratory single centre study. <i>BMC Nephrology</i> , 2012, 13, 134.	1.8	23
146	Cultural adaptation and validation of the "Kidney Disease and Quality of Life - Short Form (KDQOL-SF,®) version 1.3" questionnaire in Egypt. <i>BMC Nephrology</i> , 2012, 13, 170.	1.8	34
147	Arthroscopic guided biopsy and radiofrequency thermoablation of a benign neoplasm of the tibial spines area: a treatment option. <i>BMC Musculoskeletal Disorders</i> , 2012, 13, 52.	1.9	6
148	Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. <i>American Heart Journal</i> , 2012, 164, 902-909.e2.	2.7	112
149	Clinical usefulness of novel prognostic biomarkers in patients on hemodialysis. <i>Nature Reviews Nephrology</i> , 2012, 8, 141-150.	9.6	44
150	Monocyte subpopulations and cardiovascular risk in chronic kidney disease. <i>Nature Reviews Nephrology</i> , 2012, 8, 362-369.	9.6	143
151	The use of hook plate in type III and V acromio-clavicular Rockwood dislocations: Clinical and radiological midterm results and MRI evaluation in 42 patients. <i>Injury</i> , 2012, 43, 147-152.	1.7	95
152	Comparison of Calcium Acetate and Sevelamer on Vascular Function and Fibroblast Growth Factor 23 in CKD Patients: A Randomized Clinical Trial. <i>American Journal of Kidney Diseases</i> , 2012, 59, 177-185.	1.9	128
153	Effect of Renal Artery Stenting on Left Ventricular Mass: A Randomized Clinical Trial. <i>American Journal of Kidney Diseases</i> , 2012, 60, 39-46.	1.9	45
154	Smoking and hyperparathyroidism in patients with end-stage renal disease (ESRD). <i>Journal of Nephrology</i> , 2012, 25, 75-83.	2.0	2
155	Measuring asymmetric dimethylarginine (ADMA) in CKD: a comparison between enzyme-linked immunosorbent assay and liquid chromatography-electrospray tandem mass spectrometry. <i>Journal of Nephrology</i> , 2012, 25, 1016-1022.	2.0	17
156	Heart rate, age and the risk of progression to kidney failure in patients with CKD. <i>Journal of Nephrology</i> , 2012, 25, 20-27.	2.0	9
157	The MAURO study: baseline characteristics and compliance with guidelines targets. <i>Journal of Nephrology</i> , 2012, 25, 1081-1090.	2.0	18
158	Preoperative radiofrequency ablation in painful osteolytic long bone metastases. <i>Acta Orthopaedica Belgica</i> , 2012, 78, 523-30.	0.4	4
159	The ENPP1 Q121 Variant Predicts Major Cardiovascular Events in High-Risk Individuals. <i>Diabetes</i> , 2011, 60, 1000-1007.	0.6	37
160	Adiponectin and Leptin in Chronic Kidney Disease: Causal Factors or Mere Risk Markers?. , 2011, 21, 87-91.		41
161	Adding Up the Evidence: Systematic Reviews and Meta-Analyses. <i>Nephron Clinical Practice</i> , 2011, 119, c310-c316.	2.3	9
162	The use of group sequential, information-based sample size re-estimation in the design of the PRIMO study of chronic kidney disease. <i>Clinical Trials</i> , 2011, 8, 165-174.	1.6	20

#	ARTICLE	IF	CITATIONS
163	Sympathoinhibitory effects of statins in chronic kidney disease. <i>Journal of Hypertension</i> , 2011, 29, 2064-2067.	0.5	3
164	Dyslipidemia in Chronic Renal Disease. , 2011, , 183-189.		0
165	The Dilemma of Making Recommendations Based on Weak Evidence. <i>Seminars in Dialysis</i> , 2011, 24, 27-29.	1.3	0
166	Aging and Left Ventricular Mass and Function in People with End-Stage Renal Disease. <i>Journal of the American Geriatrics Society</i> , 2011, 59, 1636-1641.	2.6	7
167	Obesity and the Epidemiology and Prevention of Kidney Disease: Waist Circumference Versus Body Mass Index. <i>American Journal of Kidney Diseases</i> , 2011, 58, 157-159.	1.9	14
168	The dysfunctional endothelium in CKD and in cardiovascular disease: mapping the origin(s) of cardiovascular problems in CKD and of kidney disease in cardiovascular conditions for a research agenda. <i>Kidney International Supplements</i> , 2011, 1, 6-9.	14.2	57
169	The lingering dilemma of arterial pressure in CKD: what do we know, where do we go?. <i>Kidney International Supplements</i> , 2011, 1, 17-20.	14.2	9
170	Low Triiodothyronine Alters Flow-Mediated Vasodilatation in Advanced Nondiabetic Kidney Disease. <i>American Journal of Nephrology</i> , 2011, 33, 25-32.	3.1	54
171	When to start dialysis: updated guidance following publication of the Initiating Dialysis Early and Late (IDEAL) study. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2082-2086.	0.7	140
172	Sympathetic Nerve Traffic and Asymmetric Dimethylarginine in Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 2620-2627.	4.5	46
173	Inflammation and Asymmetric Dimethylarginine for Predicting Death and Cardiovascular Events in ESRD Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1714-1721.	4.5	98
174	Prognosis of CKD Patients Receiving Outpatient Nephrology Care in Italy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 2421-2428.	4.5	88
175	Ranolazine can markedly increase tacrolimus blood levels. <i>CKJ: Clinical Kidney Journal</i> , 2011, 4, 44-45.	2.9	2
176	Phosphate May Promote CKD Progression and Attenuate Renoprotective Effect of ACE Inhibition. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 1923-1930.	6.1	190
177	Matching, an Appealing Method to Avoid Confounding?. <i>Nephron Clinical Practice</i> , 2011, 118, c315-c318.	2.3	64
178	Reporting of Interaction. <i>Nephron Clinical Practice</i> , 2011, 119, c158-c161.	2.3	19
179	Sample Size Calculations. <i>Nephron Clinical Practice</i> , 2011, 118, c319-c323.	2.3	119
180	Genetic Association Studies: Discovery of the Genetic Basis of Renal Disease. <i>Nephron Clinical Practice</i> , 2011, 119, c236-c239.	2.3	4

#	ARTICLE	IF	CITATIONS
181	Interaction on an Additive Scale. Nephron Clinical Practice, 2011, 119, c154-c157.	2.3	18
182	Survival Analysis II: Cox Regression. Nephron Clinical Practice, 2011, 119, c255-c260.	2.3	57
183	Survival Analysis I: The Kaplan-Meier Method. Nephron Clinical Practice, 2011, 119, c83-c88.	2.3	98
184	How to Deal with Continuous and Dichotomic Outcomes in Epidemiological Research: Linear and Logistic Regression Analyses. Nephron Clinical Practice, 2011, 118, c399-c406.	2.3	21
185	Left Ventricular Mass Index as an Outcome Measure in Clinical Trials in Dialysis Patients: A Word of Caution. American Journal of Nephrology, 2011, 33, 370-372.	3.1	11
186	ACE Inhibition Is Renoprotective among Obese Patients with Proteinuria. Journal of the American Society of Nephrology: JASN, 2011, 22, 1122-1128.	6.1	119
187	Cardiovascular and renal medicine, an expanding territory. Kidney International Supplements, 2011, 1, 1.	14.2	2
188	Abdominal obesity modifies the risk of hypertriglyceridemia for all-cause and cardiovascular mortality in hemodialysis patients. Kidney International, 2011, 79, 765-772.	5.2	39
189	Vitamin D Receptor Activation and Left Ventricular Hypertrophy in Advanced Kidney Disease. American Journal of Nephrology, 2011, 33, 139-149.	3.1	36
190	Major pathways of the reno-cardiovascular link: the sympathetic and renin-angiotensin systems. Kidney International Supplements, 2011, 1, 13-16.	14.2	11
191	The complexity of the cardio-renal link: taxonomy, syndromes, and diseases. Kidney International Supplements, 2011, 1, 2-5.	14.2	24
192	Arterial aging and arterial disease: interplay between central hemodynamics, cardiac work, and organ flow-implications for CKD and cardiovascular disease. Kidney International Supplements, 2011, 1, 10-12.	14.2	44
193	Cardiovascular and non-cardiovascular mortality in dialysis patients: where is the link?. Kidney International Supplements, 2011, 1, 21-23.	14.2	37
194	Ultrafiltration intensification in hemodialysis patients improves hypertension but increases AV fistula complications and cardiovascular events.. Journal of Nephrology, 2011, 24, 465-473.	2.0	31
195	Neuropeptide Y receptor Y2 gene polymorphism interacts with plasma neuropeptide Y levels in predicting left ventricular hypertrophy in dialysis patients. Journal of Hypertension, 2010, 28, 1745-1751.	0.5	9
196	Vasopressin beyond water: implications for renal diseases. Current Opinion in Nephrology and Hypertension, 2010, 19, 499-504.	2.0	37
197	Vitamin D receptor (VDR) gene polymorphism is associated with left ventricular (LV) mass and predicts left ventricular hypertrophy (LVH) progression in end-stage renal disease (ESRD) patients. Journal of Bone and Mineral Research, 2010, 25, 313-319.	2.8	59
198	The Gore-Tex biomaterial mesh as temporary divisor in two times surgery for spinal and pelvic tumors. Musculoskeletal Surgery, 2010, 94, 21-24.	1.5	0

#	ARTICLE	IF	CITATIONS
199	Chordoma: clinical characteristics, management and prognosis of a case series of 25 patients. BMC Cancer, 2010, 10, 22.	2.6	108
200	Ectopic primary type A thymoma located in two thoracic vertebrae: a case report. BMC Cancer, 2010, 10, 322.	2.6	10
201	Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guidelines: a European Renal Best Practice (ERBP) commentary statement. Nephrology Dialysis Transplantation, 2010, 25, 3823-3831.	0.7	85
202	The Relationship between Hemoglobin Levels and Endothelial Functions in Diabetes Mellitus. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 45-50.	4.5	33
203	Case-Control Studies – An Efficient Observational Study Design. Nephron Clinical Practice, 2010, 114, c1-c4.	2.3	18
204	Observational Studies Are Complementary to Randomized Controlled Trials. Nephron Clinical Practice, 2010, 114, c173-c177.	2.3	39
205	Nebivolol Improves Renal Function in Patients Who Underwent Angioplasty due to Renal Artery Stenosis: A Pilot Study. Nephron Clinical Practice, 2010, 114, c213-c217.	2.3	24
206	Selection Bias and Information Bias in Clinical Research. Nephron Clinical Practice, 2010, 115, c94-c99.	2.3	227
207	Stratification for Confounding – Part 1: The Mantel-Haenszel Formula. Nephron Clinical Practice, 2010, 116, c317-c321.	2.3	37
208	Soluble E-Selectin Is an Inverse and Independent Predictor of Left Ventricular Wall Thickness in End-Stage Renal Disease Patients. Nephron Clinical Practice, 2010, 114, c74-c80.	2.3	5
209	Measures of Disease Frequency: Prevalence and Incidence. Nephron Clinical Practice, 2010, 115, c17-c20.	2.3	71
210	Left Ventricular Systolic Dysfunction. Hypertension, 2010, 56, 187-188.	2.7	20
211	Stratification for Confounding – Part 2: Direct and Indirect Standardization. Nephron Clinical Practice, 2010, 116, c322-c325.	2.3	33
212	Measures of Effect in Epidemiological Research. Nephron Clinical Practice, 2010, 115, c91-c93.	2.3	7
213	Sample size calculations: basic principles and common pitfalls. Nephrology Dialysis Transplantation, 2010, 25, 1388-1393.	0.7	302
214	Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease. Kidney International, 2010, 77, 225-231.	5.2	60
215	FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease. Kidney International, 2010, 78, 679-685.	5.2	143
216	Hyperhomocysteinemia: a renal and cardiovascular risk factor?. Nature Reviews Nephrology, 2010, 6, 695-696.	9.6	6

#	ARTICLE	IF	CITATIONS
217	Statistical methods for the assessment of prognostic biomarkers (Part I): Discrimination. Nephrology Dialysis Transplantation, 2010, 25, 1399-1401.	0.7	68
218	Epidemiology of CKD in Europe: an uncertain scenario. Nephrology Dialysis Transplantation, 2010, 25, 1731-1733.	0.7	49
219	Mendelian randomization: use of genetics to enable causal inference in observational studies. Nephrology Dialysis Transplantation, 2010, 25, 1394-1398.	0.7	84
220	Hemofiltration and Hemodiafiltration Reduce Intradialytic Hypotension in ESRD. Journal of the American Society of Nephrology: JASN, 2010, 21, 1798-1807.	6.1	239
221	Statistical methods for the assessment of prognostic biomarkers(part II): calibration and re-classification. Nephrology Dialysis Transplantation, 2010, 25, 1402-1405.	0.7	41
222	Prevalence and Prognosis of Mild Anemia in Non-Dialysis Chronic Kidney Disease: A Prospective Cohort Study in Outpatient Renal Clinics. American Journal of Nephrology, 2010, 32, 533-540.	3.1	28
223	The issue of studying the effect of interventions in renal replacement therapy – to what extent may we be deceived by selection and competing risk?. Nephrology Dialysis Transplantation, 2010, 25, 3836-3839.	0.7	26
224	What makes plaques vulnerable in CKD?: a fresh look at metalloproteinases. Kidney International, 2010, 78, 1206-1208.	5.2	2
225	Detection of Pulmonary Congestion by Chest Ultrasound in Dialysis Patients. JACC: Cardiovascular Imaging, 2010, 3, 586-594.	5.3	232
226	Chronic kidney disease and end-stage renal disease—a review produced to contribute to the report 'the status of health in the European union: towards a healthier Europe'. CKJ: Clinical Kidney Journal, 2010, 3, 213-224.	2.9	47
227	Endothelial Dysfunction, Nitric Oxide Bioavailability, and Asymmetric Dimethyl Arginine. , 2010, , 235-244.		3
228	Traditional and nontraditional risk factors as predictors of cerebrovascular events in patients with end stage renal disease. Journal of Hypertension, 2010, 28, 2468-2474.	0.5	14
229	Cardiomyopathy in Chronic Kidney Disease and in End-stage Renal Disease. , 2010, , 175-187.		0
230	Promoting scientific collaboration and education in cardiovascular-renal medicine: EURECAM: An ERA-EDTA-based working group. CKJ: Clinical Kidney Journal, 2009, 2, 522-525.	2.9	1
231	Study Designs in Clinical Research. Nephron Clinical Practice, 2009, 113, c218-c221.	2.3	54
232	Cohort Studies: Prospective versus Retrospective. Nephron Clinical Practice, 2009, 113, c214-c217.	2.3	233
233	The Randomized Controlled Trial. Nephron Clinical Practice, 2009, 113, c337-c342.	2.3	20
234	Biomarkers of Left Atrial Volume. Hypertension, 2009, 54, 818-824.	2.7	49

#	ARTICLE	IF	CITATIONS
235	Comorbidity data collection by renal registries--a remaining challenge. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 2311-2313.	0.7	11
236	Blood pressure control: hydrogen sulfide, a new gasotransmitter, takes stage. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 1394-1396.	0.7	30
237	The sweetness of glitazones: randomized trials needed. <i>Nature Reviews Nephrology</i> , 2009, 5, 497-498.	9.6	3
238	Screening: why, when, and how. <i>Kidney International</i> , 2009, 76, 694-699.	5.2	19
239	Hemoglobin is inversely related to flow-mediated dilatation in chronic kidney disease. <i>Kidney International</i> , 2009, 75, 1316-1321.	5.2	33
240	An update on renal replacement therapy in Europe: ERA-EDTA Registry data from 1997 to 2006. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 3557-3566.	0.7	129
241	The future of European Nephrology 'Guidelines'--a declaration of intent by European Renal Best Practice (ERBP). <i>CKJ: Clinical Kidney Journal</i> , 2009, 2, 213-221.	2.9	7
242	The Databases. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, S18-S22.	4.5	21
243	The 2007 ERA-EDTA Registry Annual Report--a Precis. <i>CKJ: Clinical Kidney Journal</i> , 2009, 2, 514-521.	2.9	23
244	An osteoporotic hip fracture in a 14-year-old girl undergoing chemotherapy and operated for knee osteosarcoma. <i>Journal of Orthopaedics and Traumatology</i> , 2009, 10, 151-154.	2.3	1
245	Mazabraudâ€™s syndrome: a new case and review of the literature. <i>International Orthopaedics</i> , 2009, 33, 605-610.	1.9	65
246	The role of FDG-PET in distinguishing between septic and aseptic loosening in hip prosthesis: a review of literature. <i>International Orthopaedics</i> , 2009, 33, 1-5.	1.9	50
247	Klotho Variants and Chronic Hemodialysis Mortality. <i>Journal of Bone and Mineral Research</i> , 2009, 24, 1847-1855.	2.8	54
248	Vitamin D levels and patient outcome in chronic kidney disease. <i>Kidney International</i> , 2009, 75, 88-95.	5.2	384
249	Diagnostic methods I: sensitivity, specificity, and other measures of accuracy. <i>Kidney International</i> , 2009, 75, 1257-1263.	5.2	181
250	Biopsy can determinate tumoral track contamination: A case report of chondrosarcoma. <i>European Journal of Radiology Extra</i> , 2009, 72, e79-e81.	0.1	10
251	Abdominal Obesity and All-Cause and Cardiovascular Mortality in End-Stage Renal Disease. <i>Journal of the American College of Cardiology</i> , 2009, 53, 1265-1272.	2.8	279
252	Systematic reviews and meta-analyses: when they are useful and when to be careful. <i>Kidney International</i> , 2009, 76, 1130-1136.	5.2	31

#	ARTICLE	IF	CITATIONS
253	Methylarginines and mortality in patients with end stage renal disease: A prospective cohort study. <i>Atherosclerosis</i> , 2009, 207, 541-545.	0.8	60
254	The effect of joint exposures: examining the presence of interaction. <i>Kidney International</i> , 2009, 75, 677-681.	5.2	166
255	Diagnostic methods 2: receiver operating characteristic (ROC) curves. <i>Kidney International</i> , 2009, 76, 252-256.	5.2	60
256	Clinical Implications of Elevated Asymmetric Dimethylarginine in Chronic Kidney Disease and End-Stage Renal Disease. , 2009, 19, 25-28.		9
257	Out-of-office blood pressure monitoring in chronic kidney disease. <i>Blood Pressure Monitoring</i> , 2009, 14, 2-11.	0.8	65
258	Thyroid, Renal Function, and Cardiac Outcome. , 2009, , 191-201.		1
259	Cardiovascular risk in patients with chronic kidney disease: Not high enough to enter the major league?. <i>Current Hypertension Reports</i> , 2008, 10, 1-2.	3.5	2
260	Spontaneous compartment syndrome in a patient with diabetes and statin administration: a case report. <i>Journal of Orthopaedics and Traumatology</i> , 2008, 9, 101-103.	2.3	13
261	Clinical and radiological midterm results from using the Fixion expandable intramedullary nail in transverse and short oblique fractures of femur and tibia. <i>Journal of Orthopaedics and Traumatology</i> , 2008, 9, 123-128.	2.3	6
262	Kidney Function and Risk Factors for Left Ventricular Hypertrophy in Untreated Uncomplicated Essential Hypertension. <i>American Journal of Kidney Diseases</i> , 2008, 52, 74-84.	1.9	27
263	Biosimilars and biopharmaceuticals: what the nephrologists need to know—a position paper by the ERA-EDTA Council. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 3731-3737.	0.7	62
264	An unusual case of osteomyelitis of IV metacarpus mimicking osteosarcoma. <i>European Journal of Radiology Extra</i> , 2008, 66, e59-e63.	0.1	0
265	European best practice quo vadis? From European best practice guidelines (EBPG) to European renal best practice (ERBP). <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 2162-2166.	0.7	59
266	Screening for Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 616-623.	4.5	89
267	FGF-23 in dialysis patients: ready for prime time?. <i>Nephrology Dialysis Transplantation</i> , 2008, 24, 1078-1081.	0.7	10
268	Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) hepatitis C guidelines: a European Renal Best Practice (ERBP) position statement. <i>Nephrology Dialysis Transplantation</i> , 2008, 24, 719-727.	0.7	41
269	Agreement between methods. <i>Kidney International</i> , 2008, 74, 1116-1120.	5.2	83
270	The Burden of Cardiovascular Disease in Patients with Chronic Kidney Disease and in End-Stage Renal Disease. , 2008, 161, 63-67.		11

#	ARTICLE	IF	CITATIONS
271	Gammaglutamyltransferase in ESRD as a predictor of all-cause and cardiovascular mortality: another facet of oxidative stress burden. <i>Kidney International</i> , 2008, 74, S64-S66.	5.2	23
272	Urotensin II and Cardiomyopathy in End-Stage Renal Disease. <i>Hypertension</i> , 2008, 51, 326-333.	2.7	19
273	Rate of Atherosclerotic Plaque Formation Predicts Cardiovascular Events in ESRD. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 757-763.	6.1	41
274	Endothelial Dysfunction and C-Reactive Protein Are Risk Factors for Diabetes in Essential Hypertension. <i>Diabetes</i> , 2008, 57, 167-171.	0.6	72
275	The analysis of survival data in nephrology: basic concepts and methods of Cox regression. <i>Kidney International</i> , 2008, 74, 705-709.	5.2	72
276	Survival analysis: time-dependent effects and time-varying risk factors. <i>Kidney International</i> , 2008, 74, 994-997.	5.2	219
277	The analysis of survival data: the Kaplan-Meier method. <i>Kidney International</i> , 2008, 74, 560-565.	5.2	179
278	Testing for causality and prognosis: etiological and prognostic models. <i>Kidney International</i> , 2008, 74, 1512-1515.	5.2	45
279	Obesity, diabetes, adiponectin and the kidney: a podocyte affair. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 3767-3770.	0.7	17
280	The obesity epidemics in ESRD: from wasting to waist?. <i>Nephrology Dialysis Transplantation</i> , 2008, 24, 376-380.	0.7	35
281	Asymmetric dimethylarginine: a novel marker of risk and a potential target for therapy in chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2008, 17, 609-615.	2.0	60
282	Vascular endothelial growth factor, left ventricular dysfunction and mortality in hemodialysis patients. <i>Journal of Hypertension</i> , 2008, 26, 1875-1882.	0.5	24
283	Type-2 diabetes and endothelial dysfunction: exploring the road to disease in the reverse direction. <i>Journal of Hypertension</i> , 2008, 26, 2096-2100.	0.5	2
284	Urotensin II: a cardiovascular and renal update. <i>Current Opinion in Nephrology and Hypertension</i> , 2008, 17, 199-204.	2.0	24
285	Asymmetric dimethyl-arginine (ADMA) response to inflammation in acute infections. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 801-806.	0.7	592
286	Clinical policies on the management of chronic kidney disease patients in Italy. <i>Nephrology Dialysis Transplantation</i> , 2007, 23, 621-626.	0.7	14
287	Quality of care in end-stage renal disease: the importance of comparing 'apples with apples'. <i>Nephrology Dialysis Transplantation</i> , 2007, 23, 1116-1116.	0.7	9
288	Searching for biomarker patterns characterizing carotid atherosclerotic burden in patients with reduced renal function. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 3521-3526.	0.7	32

#	ARTICLE	IF	CITATIONS
289	Clinical Databases and the QUEST Initiative. <i>Blood Purification</i> , 2007, 25, 219-220.	1.8	7
290	Prognostic value of the New York Heart Association classification in end-stage renal disease. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 1377-1382.	0.7	34
291	How important is echocardiography for risk stratification in follow-up of patients with chronic kidney disease?. <i>Nature Clinical Practice Nephrology</i> , 2007, 3, 178-179.	2.0	19
292	Endothelial dysfunction in CKD: a new player in town?. <i>Nephrology Dialysis Transplantation</i> , 2007, 23, 783-785.	0.7	22
293	A New Perspective for the Treatment of Renal Diseases?. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 1365-1367.	6.1	4
294	Left Atrial Volume Monitoring and Cardiovascular Risk in Patients with End-Stage Renal Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 1316-1322.	6.1	78
295	An Additive Effect of Endothelial Nitric Oxide Synthase Gene Polymorphisms Contributes to the Severity of Atherosclerosis in Patients on Dialysis. <i>American Journal of Hypertension</i> , 2007, 20, 758-763.	2.0	9
296	Guest Editor: Rajiv Agarwal: Cardiovascular Risk Profile Assessment and Medication Control Should Come First. <i>Seminars in Dialysis</i> , 2007, 20, 405-408.	1.3	1
297	CARDIOVASCULAR AND SURVIVAL PARADOXES IN DIALYSIS PATIENTS: It Is Important to Lower Homocysteine in Dialysis Patients. <i>Seminars in Dialysis</i> , 2007, 20, 530-533.	1.3	8
298	Neuropeptide Y and Markers of Osteoblast Activity in Dialysis Patients: A Cross-Sectional Study. <i>American Journal of Kidney Diseases</i> , 2007, 50, 1001-1008.	1.9	9
299	Urotensin II and Biomarkers of Endothelial Activation and Atherosclerosis in End-Stage Renal Disease. <i>American Journal of Hypertension</i> , 2006, 19, 505-510.	2.0	21
300	Renal impairment: a risk factor for ischemic heart disease. <i>Current Opinion in Pharmacology</i> , 2006, 6, 221-225.	3.5	3
301	Low triiodothyronine and cardiomyopathy in patients with end-stage renal disease. <i>Journal of Hypertension</i> , 2006, 24, 2039-2046.	0.5	55
302	Asymmetric dimethylarginine: a new player in the pathogenesis of renal disease?. <i>Current Opinion in Nephrology and Hypertension</i> , 2006, 15, 314-320.	2.0	43
303	Endothelial dysfunction in subcutaneous small resistance arteries and cardiovascular events. <i>Journal of Hypertension</i> , 2006, 24, 1900-1901.	0.5	1
304	Asymmetric dimethylarginine (ADMA): a cardiovascular and renal risk factor on the move. <i>Journal of Hypertension</i> , 2006, 24, 611-619.	0.5	60
305	Left atrial volume in end-stage renal disease: a prospective cohort study. <i>Journal of Hypertension</i> , 2006, 24, 1173-1180.	0.5	90
306	Asymmetric dimethylarginine (ADMA) as a cardiovascular risk factor in end-stage renal disease (ESRD). <i>European Journal of Clinical Pharmacology</i> , 2006, 62, 131-135.	1.9	8

#	ARTICLE	IF	CITATIONS
307	The Determinants of Endothelial Dysfunction in CKD: Oxidative Stress and Asymmetric Dimethylarginine. <i>American Journal of Kidney Diseases</i> , 2006, 47, 42-50.	1.9	285
308	Mendelian Randomization: A New Approach to Studying Epidemiology in ESRD. <i>American Journal of Kidney Diseases</i> , 2006, 47, 332-341.	1.9	43
309	Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 991-998.	0.7	140
310	The E-selectin gene polymorphism and carotid atherosclerosis in end-stage renal disease. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 1921-1926.	0.7	18
311	Subclinical hypothyroidism is linked to micro-inflammation and predicts death in continuous ambulatory peritoneal dialysis. <i>Nephrology Dialysis Transplantation</i> , 2006, 22, 538-544.	0.7	94
312	Is silent cerebral infarction associated with vascular events in patients undergoing hemodialysis?. <i>Nature Clinical Practice Nephrology</i> , 2006, 2, 20-21.	2.0	0
313	Is oxidative stress implicated in high bone turnover in end-stage renal disease (ESRD)?. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 1735-1736.	0.7	0
314	Dissecting Inflammation in ESRD: Do Cytokines and C-Reactive Protein Have a Complementary Prognostic Value for Mortality in Dialysis Patients?. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, S169-S173.	6.1	101
315	Uric Acid and Endothelial Dysfunction in Essential Hypertension. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 1466-1471.	6.1	202
316	Letter by Kielstein et al Regarding Article, "Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure". <i>Circulation</i> , 2006, 114, e242; author reply e243.	1.6	0
317	Pre- and Postdialysis Blood Pressures Are Imprecise Estimates of Interdialytic Ambulatory Blood Pressure. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 389-398.	4.5	200
318	Inflammation as a Mediator of the Link between Mild to Moderate Renal Insufficiency and Endothelial Dysfunction in Essential Hypertension. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, S64-S68.	6.1	39
319	Left Ventricular Systolic Function Monitoring in Asymptomatic Dialysis Patients: A Prospective Cohort Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 1460-1465.	6.1	48
320	Endothelial Dysfunction and the Kidney: Emerging Risk Factors for Renal Insufficiency and Cardiovascular Outcomes in Essential Hypertension. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, S61-S63.	6.1	64
321	Neuropeptide Y as a far-reaching neuromediator: from energy balance and cardiovascular regulation to central integration of weight and bone mass control mechanisms. Implications for human diseases. <i>Current Opinion in Nephrology and Hypertension</i> , 2005, 14, 25-32.	2.0	11
322	Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction, and myocardial pathology in patients with ESRD. <i>Kidney International</i> , 2005, 67, 2330-2337.	5.2	116
323	Prognostic value of 24-hour ambulatory blood pressure monitoring and of night/day ratio in nondiabetic, cardiovascular events-free hemodialysis patients. <i>Kidney International</i> , 2005, 68, 1294-1302.	5.2	114
324	Hyperhomocysteinemia and arteriovenous fistula thrombosis in hemodialysis patients. <i>American Journal of Kidney Diseases</i> , 2005, 45, 702-707.	1.9	42

#	ARTICLE	IF	CITATIONS
325	Asymmetric Dimethylarginine: A Cardiovascular Risk Factor and a Uremic Toxin Coming of Age?. American Journal of Kidney Diseases, 2005, 46, 186-202.	1.9	157
326	Inflammation Markers, Adhesion Molecules, and All-Cause and Cardiovascular Mortality in Patients with ESRD. Journal of the American Society of Nephrology: JASN, 2005, 16, S83-S88.	6.1	217
327	Asymmetrical Dimethylarginine Predicts Progression to Dialysis and Death in Patients with Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2005, 16, 2449-2455.	6.1	352
328	Low Triiodothyronine. Journal of the American Society of Nephrology: JASN, 2005, 16, 2789-2795.	6.1	132
329	Parasympathetic neuropathy and LVH. Nephrology Dialysis Transplantation, 2005, 20, 1011-1011.	0.7	0
330	QUality European Studies (QUEST)â€“a step forward in the quality of RRT care. Nephrology Dialysis Transplantation, 2005, 20, 2005-2006.	0.7	21
331	Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet, The, 2005, 365, 939-946.	13.7	594
332	Asymmetric Dimethylarginine, L-Arginine, and Endothelial Dysfunction in Essential Hypertension. Journal of the American College of Cardiology, 2005, 46, 518-523.	2.8	239
333	Predictors of Cardiovascular Death in ESRD. Seminars in Nephrology, 2005, 25, 358-362.	1.6	76
334	Adipose tissue cytokines, insulin sensitivity, inflammation, and cardiovascular outcomes in end-stage renal disease patients. , 2005, 15, 125-130.		45
335	Atherosclerosis and the Glu298Asp Polymorphism of the eNOS Gene in White Patients With End-Stage Renal Disease. American Journal of Hypertension, 2005, 18, 1549-1555.	2.0	14
336	Prognostic Value of Echocardiographic Indicators of Left Ventricular Systolic Function in Asymptomatic Dialysis Patients. Journal of the American Society of Nephrology: JASN, 2004, 15, 1029-1037.	6.1	180
337	Analysis of the Relationship between Norepinephrine and Asymmetric Dimethyl Arginine Levels among Patients with End-Stage Renal Disease. Journal of the American Society of Nephrology: JASN, 2004, 15, 435-441.	6.1	93
338	Inflammatory proteins as predictors of cardiovascular disease in patients with end-stage renal disease. Nephrology Dialysis Transplantation, 2004, 19, v67-v72.	0.7	62
339	Endothelial Dysfunction and Mild Renal Insufficiency in Essential Hypertension. Circulation, 2004, 110, 821-825.	1.6	94
340	Left ventricular mass monitoring in the follow-up of dialysis patients: Prognostic value of left ventricular hypertrophy progression. Kidney International, 2004, 65, 1492-1498.	5.2	299
341	HYPERTENSION IN HEMODIALYSIS PATIENTS: Cardiac Consequences of Hypertension in Hemodialysis Patients. Seminars in Dialysis, 2004, 17, 299-303.	1.3	38
342	Heart valve calcifications, survival, and cardiovascular risk in hemodialysis patients. American Journal of Kidney Diseases, 2004, 43, 479-484.	1.9	47

#	ARTICLE	IF	CITATIONS
343	Achievement of target blood pressure levels in chronic kidney disease: a salty question?. American Journal of Kidney Diseases, 2004, 43, 782-795.	1.9	91
344	Salivary and lacrimal secretion is reduced in patients with ESRD. American Journal of Kidney Diseases, 2003, 42, 722-728.	1.9	57
345	Chlamydia pneumoniae, overall and cardiovascular mortality in end-stage renal disease (ESRD). Kidney International, 2003, 64, 579-584.	5.2	22
346	ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease. Atherosclerosis Supplements, 2003, 4, 23-28.	1.2	95
347	Hepatocyte Growth Factor and Left Ventricular Geometry in End-Stage Renal Disease. Hypertension, 2003, 41, 88-92.	2.7	27
348	The importance of diabetic nephropathy in current nephrological practice. Nephrology Dialysis Transplantation, 2003, 18, 1716-1725.	0.7	52
349	Prospective Study of Neuropeptide Y as an Adverse Cardiovascular Risk Factor in End-Stage Renal Disease. Journal of the American Society of Nephrology: JASN, 2003, 14, 2611-2617.	6.1	48
350	Genetic polymorphism of the renin-angiotensin-aldosterone system and arterial hypertension in the Italian population. Journal of Hypertension, 2003, 21, 1853-1860.	0.5	47
351	Neuropeptide Y, left ventricular mass and function in patients with end stage renal disease. Journal of Hypertension, 2003, 21, 1355-1362.	0.5	23
352	Salt sensitivity phenotype. Journal of Hypertension, 2003, 21, 869-870.	0.5	2
353	Arterial pressure components and cardiovascular risk in end-stage renal disease. Nephrology Dialysis Transplantation, 2003, 18, 249-252.	0.7	25
354	Inflammation and Atherosclerosis in End-Stage Renal Disease. Blood Purification, 2003, 21, 29-36.	1.8	76
355	Plasma Norepinephrine Predicts Survival and Incident Cardiovascular Events in Patients With End-Stage Renal Disease. Circulation, 2002, 105, 1354-1359.	1.6	485
356	Norepinephrine and Concentric Hypertrophy in Patients With End-Stage Renal Disease. Hypertension, 2002, 40, 41-46.	2.7	123
357	Endothelial Damage, Asymmetric Dimethylarginine and Cardiovascular Risk in End-Stage Renal Disease. Blood Purification, 2002, 20, 469-472.	1.8	29
358	Nocturnal Hypoxemia: A Neglected Cardiovascular Risk Factor in End-Stage Renal Disease?. Blood Purification, 2002, 20, 120-123.	1.8	20
359	Troponin is related to left ventricular mass and predicts all-cause and cardiovascular mortality in hemodialysis patients. American Journal of Kidney Diseases, 2002, 40, 68-75.	1.9	144
360	Low parathyroid hormone and pentosidine in hemodialysis patients. American Journal of Kidney Diseases, 2002, 40, 810-815.	1.9	20

#	ARTICLE	IF	CITATIONS
361	Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. <i>Kidney International</i> , 2002, 61, 609-614.	5.2	247
362	Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. <i>Kidney International</i> , 2002, 62, 339-345.	5.2	194
363	Inflammation and outcome in end-stage renal failure: Does female gender constitute a survival advantage?. <i>Kidney International</i> , 2002, 62, 1791-1798.	5.2	175
364	Diagnostic value of troponin T for alterations in left ventricular mass and function in dialysis patients. <i>Kidney International</i> , 2002, 62, 1884-1890.	5.2	66
365	Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. <i>Lancet, The</i> , 2001, 358, 2113-2117.	13.7	993
366	Left ventricular hypertrophy and nocturnal hypoxemia in hemodialysis patients. <i>Journal of Hypertension</i> , 2001, 19, 287-293.	0.5	52
367	Diagnostic potential of cardiac natriuretic peptides in dialysis patients. <i>Kidney International</i> , 2001, 59, 1559-1566.	5.2	145
368	ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies ¹ . <i>Kidney International</i> , 2000, 57, 274-281.	5.2	75
369	Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. <i>Lancet, The</i> , 1999, 354, 359-364.	13.7	800
370	Prediction of left ventricular geometry by clinic, pre-dialysis and 24-h ambulatory BP monitoring in hemodialysis patients. <i>Journal of Hypertension</i> , 1999, 17, 1751-1758.	0.5	92
371	Nocturnal hypoxemia, night-day arterial pressure changes and left ventricular geometry in dialysis patients. <i>Kidney International</i> , 1998, 53, 1078-1084.	5.2	120
372	Plasma adrenomedullin during acute changes in intravascular volume in hemodialysis patients. <i>Kidney International</i> , 1998, 54, 1697-1703.	5.2	38
373	Reproducibility of the response to short-term low salt intake in essential hypertension. <i>Journal of Hypertension</i> , 1996, 14, 1455-1459.	0.5	39
374	Influence of Cardiovascular Damage and Residual Renal Function on Plasma Endothelin in Chronic Renal Failure. <i>Nephron</i> , 1993, 63, 291-295.	1.8	17
375	Effects of Potassium on Sodium Balance, Renin, Noradrenaline and Arterial Pressure. <i>Journal of Hypertension</i> , 1985, 3, 67-72.	0.5	28
376	The Renal Tubular Defect of Bartter's Syndrome. <i>Nephron</i> , 1982, 32, 140-148.	1.8	24